-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $180

Benzinga·12/08/2025 14:36:35
Listen to the news
RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $160 to $180.